156 related articles for article (PubMed ID: 32629079)
1. A Multi-atlas Approach for Active Bone Marrow Sparing Radiation Therapy: Implementation in the NRG-GY006 Trial.
Yusufaly T; Miller A; Medina-Palomo A; Williamson CW; Nguyen H; Lowenstein J; Leath CA; Xiao Y; Moore KL; Moxley KM; Chevere-Mourino CM; Eng TY; Zaid T; Mell LK
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1240-1247. PubMed ID: 32629079
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer.
Li N; Noticewala SS; Williamson CW; Shen H; Sirak I; Tarnawski R; Mahantshetty U; Hoh CK; Moore KL; Mell LK
Radiother Oncol; 2017 May; 123(2):325-330. PubMed ID: 28528206
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
4. The volume of
Wang SB; Liu JP; Lei KJ; Jia YM; Xu Y; Rong JF; Wang CX
Cancer Med; 2019 Dec; 8(17):7219-7226. PubMed ID: 31621208
[TBL] [Abstract][Full Text] [Related]
5. [(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients.
Wyss JC; Carmona R; Karunamuni RA; Pritz J; Hoh CK; Mell LK
Radiother Oncol; 2016 Jan; 118(1):72-8. PubMed ID: 26674924
[TBL] [Abstract][Full Text] [Related]
6. The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation.
Zhou YM; Freese C; Meier T; Go D; Khullar K; Sudhoff M; Lamba M; Kharofa J
Clin Transl Oncol; 2018 Jun; 20(6):713-718. PubMed ID: 29076030
[TBL] [Abstract][Full Text] [Related]
7. Highly Efficient Training, Refinement, and Validation of a Knowledge-based Planning Quality-Control System for Radiation Therapy Clinical Trials.
Li N; Carmona R; Sirak I; Kasaova L; Followill D; Michalski J; Bosch W; Straube W; Mell LK; Moore KL
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):164-172. PubMed ID: 27979445
[TBL] [Abstract][Full Text] [Related]
8. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
9. Optimal dose limitation strategy for bone marrow sparing in intensity-modulated radiotherapy of cervical cancer.
Bao Z; Wang D; Chen S; Chen M; Jiang D; Yang C; Liu H; Dai J; Xie C
Radiat Oncol; 2019 Aug; 14(1):118. PubMed ID: 31378200
[TBL] [Abstract][Full Text] [Related]
10. An atlas-based electron density mapping method for magnetic resonance imaging (MRI)-alone treatment planning and adaptive MRI-based prostate radiation therapy.
Dowling JA; Lambert J; Parker J; Salvado O; Fripp J; Capp A; Wratten C; Denham JW; Greer PB
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e5-11. PubMed ID: 22330995
[TBL] [Abstract][Full Text] [Related]
11. Incorporating
Franco P; Fiandra C; Arcadipane F; Trino E; Giglioli FR; Ragona R; Ricardi U
BMC Cancer; 2017 Nov; 17(1):710. PubMed ID: 29096619
[TBL] [Abstract][Full Text] [Related]
12. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric evaluation of bone marrow sparing in proton radiotherapy for cervical cancer guided by MR functional imaging.
Qin X; Gong G; Wang L; Su Y; Yin Y
Radiat Oncol; 2022 Dec; 17(1):207. PubMed ID: 36517839
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy.
Noticewala SS; Li N; Williamson CW; Hoh CK; Shen H; McHale MT; Saenz CC; Einck J; Plaxe S; Vaida F; Yashar CM; Mell LK
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):797-805. PubMed ID: 28244416
[TBL] [Abstract][Full Text] [Related]
15. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
16. Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.
Rose BS; Jee KW; Niemierko A; Murphy JE; Blaszkowsky LS; Allen JN; Lee LK; Wang Y; Drapek LC; Hong TS; Wo JY
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):747-54. PubMed ID: 26972647
[TBL] [Abstract][Full Text] [Related]
17. Extended-field bone marrow sparing radiotherapy for primary chemoradiotherapy in cervical cancer patients with para-aortic lymphadenopathy: Volumetric-modulated arc therapy versus helical tomotherapy.
Chen JL; Wang MC; Huang YS; Huang CY; Pan CK; Hsu CY; Lan KH; Kuo SH
J Xray Sci Technol; 2020; 28(1):111-124. PubMed ID: 31904003
[TBL] [Abstract][Full Text] [Related]
18. Differential Response of Pelvic Bone Marrow Fluorodeoxyglucose Uptake in Patients Receiving Concurrent Chemoradiotherapy.
Robinson M; Muirhead R; McGowan DR; Chu KY; Jacobs C; Hawkins MA
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):e622-e627. PubMed ID: 37339923
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of bone marrow sparing volumetric modulated arc therapy to spare active bone marrow in cervical and vaginal cancer patients: a retrospective dosimetric analysis.
Beavan M; Dundas K; Hudson F; Surjan Y; Lau A; Deshpande S; Lim K; Do V
J Med Radiat Sci; 2021 Dec; 68(4):379-388. PubMed ID: 34288534
[TBL] [Abstract][Full Text] [Related]
20. Split-field helical tomotherapy with or without chemotherapy for definitive treatment of cervical cancer.
Chang AJ; Richardson S; Grigsby PW; Schwarz JK
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):263-9. PubMed ID: 21167656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
